Carolina Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolina Alvarez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Mieke Vandamme
Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Institute for the Future, KU Leuven, Leuven, Belgium
1 shared publication - Bernardo Galvão-Castro
Advanced Laboratory of Public Health, Gonçalo Moniz Center, Fundação Oswaldo Cruz, Salvador, Bahia Brazil ; Bahian School of Medicine and Public Health (EBMSP), Salvador, Bahia Brazil
1 shared publication - Daniele Decanine
LIMI, Gonçalo Moniz Research Center (CPqGM), Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falcão 121, 40296-710 Salvador-Bahia, Brazil
1 shared publication - David Brassat
CHU Toulouse
1 shared publication - Eduardo Gotuzzo
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
1 shared publication - Giovanni López
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
1 shared publication
Latest Publications
- Open Access
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
Open AccessCD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.